Want to see GHRS full AI Analyst Report?
Top Page
GH Research
(NASDAQ:GHRS)
Select Model
Select Model
Rating:62Neutral
Price Target:
$25.00
▼(-13.55% Downside)
Action:Reiterated
Date:08/10/26
The score is driven primarily by solid financial flexibility (strong balance sheet with minimal leverage) and supportive technicals (broad uptrend with positive momentum). These are offset by weak operating fundamentals typical of early-stage biotech—no revenue, widening losses, and ongoing cash burn—and a negative P/E with no dividend support.
Positive Factors
Low leverage and equity base
Extremely low leverage gives GH Research meaningful financial flexibility while it funds clinical development. A large, stable-to-growing equity base can support continued research investment and reduce pressure from debt service as the company advances toward potential commercialization.
Negative Factors
No revenue yet
GH Research has not yet established commercial revenue, so its business model remains dependent on successful clinical progress and eventual regulatory approval. Without product sales, there is no operating revenue base to offset development expenses or demonstrate durable market demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and equity base
Extremely low leverage gives GH Research meaningful financial flexibility while it funds clinical development. A large, stable-to-growing equity base can support continued research investment and reduce pressure from debt service as the company advances toward potential commercialization.
Read all positive factors
GH Research (GHRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.61B
Dividend YieldN/A
Average Volume (3M)226.46K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS Growth-33.76%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding68,642,290
10 Day Avg. Volume344,543
30 Day Avg. Volume226,462
Financial Highlights & Ratios
PEG Ratio-3.01
Price to Book (P/B)2.77
Price to Sales (P/S)0.00
P/FCF Ratio-17.75
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.38Price Target Upside49.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
GH Research Business Overview & Revenue Model
Company Description
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments,...
GH Research Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -268.00K | -335.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -61.71M | -47.46M | -38.60M | -35.21M | -22.41M | -9.17M |
| Net Income | -62.27M | -48.26M | -38.96M | -35.59M | -22.46M | -9.20M |
Balance Sheet | ||||||
| Total Assets | 372.35M | 288.23M | 188.27M | 226.30M | 254.36M | 279.92M |
| Cash, Cash Equivalents and Short-Term Investments | 362.65M | 280.71M | 149.32M | 161.56M | 165.96M | 276.78M |
| Total Debt | 360.00K | 512.00K | 624.00K | 974.00K | 0.00 | 0.00 |
| Total Liabilities | 12.86M | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M |
| Stockholders Equity | 359.49M | 279.70M | 178.95M | 218.97M | 249.82M | 277.18M |
Cash Flow | ||||||
| Free Cash Flow | -52.53M | -43.67M | -42.33M | -33.44M | -26.27M | -15.39M |
| Operating Cash Flow | -52.39M | -43.55M | -42.28M | -33.34M | -26.20M | -15.28M |
| Investing Cash Flow | 33.99M | 46.17M | 65.14M | -54.10M | -84.69M | -104.00K |
| Financing Cash Flow | 110.71M | 139.65M | -304.00K | -204.00K | 0.00 | 286.45M |
GH Research Technical Analysis
Negative
28.92
Price Trends
27.82
Negative
25.95
Negative
20.91
Positive
Market Momentum
-1.22
Positive
30.37
Neutral
14.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Negative. The current price of 28.92 is above the 20-day moving average (MA) of 26.53, above the 50-day MA of 27.82, and above the 200-day MA of 20.91, indicating a neutral trend. The MACD of -1.22 indicates Positive momentum. The RSI at 30.37 is Neutral, neither overbought nor oversold. The STOCH value of 14.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 104 risk factors in its most recent earnings report. GH Research reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.61B | -22.64 | -20.86% | ― | ― | -33.76% | |
61 Neutral | $1.59B | -11.34 | -56.19% | ― | -32.27% | -21.09% | |
55 Neutral | $3.96B | -11.85 | -42.27% | ― | 23.86% | 19.60% | |
54 Neutral | $705.72M | 67.77 | 3.52% | ― | 7.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $554.11M | -2.75 | -188.27% | 6.80% | -17.90% | 32.10% | |
41 Neutral | $872.64M | -3.88 | -134.49% | ― | ― | 28.46% |
* Healthcare Sector Average
GHRS
GH Research
22.86
9.52
71.36%
RLAY
Relay Therapeutics
18.49
13.27
254.21%
TSHA
Taysha Gene Therapies
4.74
-0.14
-2.87%
SANA
Sana Biotechnology
2.89
-1.08
-27.20%
PHAR
Pharming Group
9.95
-5.28
-34.67%
PRME
Prime Medicine, Inc.
2.99
-3.68
-55.17%
GH Research Corporate Events
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference
Sep 11, 2026
GH Research PLC, a Dublin-based healthcare company and foreign private issuer on U.S. markets, operates in the biopharmaceutical space with a focus on innovative clinical-stage therapies. The firm regularly engages the global investment community ...
GH Research Files Q2 2026 Results and Updates Corporate Presentation
Aug 6, 2026
On August 6, 2026, GH Research PLC filed a Form 6-K reporting its second quarter 2026 financial results and business updates, and made available an updated corporate presentation as of the same date. The filing also furnished unaudited condensed c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.